Description

Each tablet contains 11?mg tofacitinib citrate in a sustained?release formulation designed to deliver steady drug exposure over 24 hours. Tofacitinib inhibits Janus kinases (JAK1 and JAK3 predominantly), disrupting key cytokine signaling pathways involved in immune response and inflammation. Though developed clinically for autoimmune conditions such as rheumatoid arthritis, in laboratory research it’s widely used to investigate immune suppression, cytokine modulation, transplant rejection models, and JAK?STAT pathway dynamics. Packaged as 30 tablets per bottle or box. Strictly for laboratory research or preclinical studies.

Tofacitinib Citrate Sustained?Release Tablets Product Specifications

Tofacitinib Citrate Sustained?Release Tablets Mechanism of Action & Research Applications

Tofacitinib Citrate acts by selectively inhibiting JAK1 and JAK3 enzymes, blocking downstream STAT signaling and reducing inflammatory cytokine activity. This mechanism provides tools for research into autoimmune disease models, transplant immunity, ulcerative colitis, and inflammatory signaling pathways. The sustained?release form enables stable drug presence in chronic models and precise pharmacokinetic studies. Frequently used in cell cultures and animal studies of immune regulation.

Tofacitinib Citrate Sustained?Release Tablets Side Effects (For Reference Only in Models)

In preclinical or analogous model systems, potential observations include increased susceptibility to infections, elevated blood pressure, elevated lipid levels, gastrointestinal disturbances, headache, and rare thromboembolic events. These findings guide safety and dosing protocols in experimental design.

Disclaimer

Tofacitinib Citrate Sustained?Release Tablets 11?mg are strictly intended for laboratory research use only. Not for human or veterinary therapeutic or diagnostic use.